A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors.

被引：6
|
作者：
Rasco, Drew W.
Li, Yufeng
Tang, Yuefen
Men, Lichuang
Wang, Hengbang
Ji, Jiao
Liang, Zhiyan
Sun, Joan
Amaya, Alex
Huang, Yingjie
Yang, Dajun
Zhai, Yifan
机构：
[1] START, San Antonio, TX USA
[2] Ascentage Pharma Grp Inc, Rockville, MD USA
[3] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China
[4] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.3125
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3125
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PHASE 1 STUDY OF AN ANTI-CD27 AGONIST AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
    Shapira-Frommer, Ronnie
    van Dongen, Marloes G. J.
    Dobrenkov, Konstantin
    Chartash, Elliot
    Liu, Fang
    Li, Claire
    Wnek, Richard
    Patel, Manish
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A2 - A2
  • [22] A phase I pharmacological and pharmacodynamic study of MK-1775, a Weel tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.
    Leijen, S.
    Schellens, J. H.
    Shapiro, G.
    Pavlick, A. C.
    Tibes, R.
    Demuth, T.
    Viscusi, J.
    Cheng, J. D.
    Xu, Y.
    Oza, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] A phase I QTc study of tivozanib in patients with advanced solid tumors.
    Chadha, Manpreet Kaur
    Infante, Jeffrey R.
    Cotreau, Monette M.
    Jacobson, Lindsey
    Strahs, Andrew Louis
    Slichenmyer, William
    Vargo, Dennis
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [24] Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors.
    Tolaney, Sara M.
    Hilton, John Frederick
    Cleary, James M.
    Gandhi, Leena
    Kwak, Eunice Lee
    Clark, Jeffrey W.
    Wolanski, Andrew
    Bell, Tracy Demeo
    Rodig, Scott J.
    Chiao, Judy H.
    Blake, David
    Shapiro, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Phase Ib study of a novel, small-molecule MDM2 inhibitor APG-115 combined with pembrolizumab in US patients with metastatic solid tumors.
    Tolcher, Anthony W.
    Karim, Raghad
    Tang, Yuefen
    Wang, Hengbang
    Ji, Jiao
    Chen, Jason
    Kaiser, Angela
    Sheladia, Piyush
    Ahmad, Mohammad
    Liang, Zhiyan
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Phase Ib study of axitinib in combination with crizotinib in patients with advanced solid tumors.
    Shepard, Dale Randall
    Bruce, Justine Yang
    Garrido-Laguna, Ignacio
    Rosbrook, Brad
    Martini, Jean-Francols
    Plthavala, Yazdi K.
    Valota, Olga
    Michaelson, M. Dror
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] Phase I pharmacokinetic (PK) study of daily imatinib in combination with docetaxel for patients with advanced solid tumors.
    Chatta, GS
    Fakih, M
    Ramalingam, S
    Belani, CP
    Ramanathan, RK
    Zamboni, N
    Friedland, D
    Lis, D
    Tutchko, S
    Egorin, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 138S - 138S
  • [28] A phase I study of MK-2206 in combination with lapatinib in patients (pts) with advanced solid tumors.
    Wisinski, Kari Braun
    Tevaarwerk, Amye
    Bell, Maria
    Burkard, Mark E.
    Eickhoff, Jens C.
    Wilding, George
    LoConte, Noelle K.
    Traynor, Anne M.
    Hoang, Tien
    Heideman, Jennifer
    Kolesar, Jill
    Liu, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Phase I study of ispinesib (SB-715992) in combination with capecitabine in patients with advanced solid tumors.
    Calvo, E
    Chu, Q
    Till, E
    Rowinsky, EK
    Patnaik, A
    Takimoto, C
    Kathman, SJ
    Williams, DD
    Bowen, CJ
    Hodge, JP
    Dar, MM
    Tolcher, AW
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9120S - 9120S
  • [30] Phase I study of ispinesib (SB-715992) in combination with docetaxel in patients with advanced solid tumors.
    Blagden, S
    Seebaran, A
    Molife, R
    Payne, M
    Reid, A
    Protheroe, A
    Kathman, S
    Williams, D
    Bowen, C
    Hodge, J
    Dar, M
    de-Bono, J
    Middleton, M
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9119S - 9119S
12345